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ABSTRACT 
 
 The Philadelphia chromosome in humans, is on oncogenic 
translocation between chromosomes 9 and 22 that gives rise to the fusion 
protein BCR-Abl.  This protein is constitutively active resulting in rapid and 
uncontrolled cell growth in affected cells.  The BCR-Abl protein is the 
hallmark feature of chronic myeloid leukemia (CML) and is seen in 
Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) cases.  
Currently, the first line of treatment is the Abl specific inhibitor Imatinib.  
Some patients will, however, develop resistance to Imatinib. 
 Research has shown how transformation of progenitor B cells with 
v-Abl, an oncogene expressed by the Abelson murine leukemia virus, 
causes rapid proliferation, prevents further differentiation and produces a 
potentially malignant transformation.  We have used progenitor B cells 
transformed with a temperature-sensitive form of the v-Abl protein that 
allows us to inactivate or re-activate v-Abl by shifting the incubation 
temperature.  We are trying to use this line as a model to study both the 
progression from pre-malignancy to malignancy in CML and Imatinib 
resistance in Ph+ ALL and CML.  These progenitor B cells, once v-Abl is 
reactivated, in most cases, will not return to their natural cell cycle.  In this 
they resemble Ph+ ALL and CML under Imatinib treatment.  With some 
manipulation these cells can break this prolonged G1 arrested phenotype 
and become a malignant cell line and resistant to Imatinib treatment. 
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 Cellular senescence can be a complicated process requiring inter-
play between a variety of players.  It serves as an alternate option to 
apoptosis, in that the cell loses proliferative potential, but does not die.  
Treatment with some cancer therapeutics will induce senescence in some 
cancers.  Such is the case with Imatinib treatment of CML and Ph+ ALL.  
By using the S9 cell line we have been able to explore the possible routes 
for breaking of prolonged G1 arrest in these Ph+ leukemias.  We inhibited 
the DNA damage sensor protein ataxia telangiectasia mutated (ATM) and 
found that prolonged G1 arrest in our S9 cells was broken. While previous 
research has suggested that the DNA damage sensor protein ataxia-
telangiectasia mutated (ATM) has little impact in CML, our research 
indicates that ATM may play a role in either senescence induction or 
release. 
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Introduction 
 
CML, ALL, BCR-Abl 
Leukemia is a type of cancer of the blood or bone marrow 
characterized by an abnormal increase of white blood cells.  The term 
leukemia includes a spectrum of diseases.  Two of which are chronic 
myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).  CML is 
a clonal disease where cells of the myeloid lineage will undergo 
unregulated clonal expansion.  This disease progresses through three 
different phases – a chronic phase, an accelerated phase, and finally blast 
crisis.7,10 In ALL it is immature lymphoblasts become malignant and 
continuously multiply in the bone marrow, crowding out normal, healthy 
cells.  The disease time course is quite short in ALL, with death occurring 
in weeks if left untreated. This type of myeloproliferative disease is 
associated with a characteristic genetic abnormality called the 
Philadelphia (Ph+) chromosome.  This chromosome is the result of a 
reciprocal translocation between the long arms of chromosomes 9 and 22.  
Specifically, the q34 region of chromosome 9 is substituted at the q11 
region of chromosome 22, denoted as t(9;22)(q34;q11).  This oncogenic 
translocation places the Abelson (Abl) gene from chromosome 9 beside 
the breakpoint cluster region (BCR) gene from chromosome 22 giving rise 
to the fusion protein BCR-Abl (Figure 1). 
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The manner and reason for this translocation are currently 
unknown.  The resultant fusion protein, BCR-Abl, is found in >90% of CML 
and ~ 30-35% of ALL patients, and has been determined to play a causal 
role in CML.7,10  The BCR-Abl protein functions as a constitutively active 
tyrosine kinase, interacting with multiple downstream actors.  The results 
of these interactions include altered cellular adhesion, inhibition of 
apoptosis, activation of mitogenic signaling, and defective DNA repair.2   
Recent advancements in targeted therapy have led to the use of a BCR-
Abl tyrosine kinase inhibitor called Imatinib (Gleevec, Novartis). Imatinib 
works by sitting in the ATP-binding site of the Abl portion of BCR-Abl, 
maintaining it in its inactive form. (FIGURE 2)  Imatinib will inhibit cell 
proliferation and tumorigenesis without inducing apoptosis.2   The use of 
imatinib greatly improved prognosis, response rate, and overall patient 
survival.  Some patients however, will develop resistance to imatinib, so 
eradication remains elusive.  While research has provided alternate 
treatments for Imatinib-resistant CML, most of these therapies still affect 
the same fusion protein, BCR-Abl.  Prognosis in CML and Ph+ ALL is quite 
poor in patients resistant to Imatinib.  Even in patients that respond well 
initially to Imatinib, treatment is not curative as BCR-Abl transcripts can 
still be detected in these patients. 
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Figure 1. Schematic of the Philadelphia Chromosome 
 
ATM, p53, mTOR pathways 
Ataxia-telangiectasia mutated is a ~370kDa protein that plays a 
central role in the DNA damage response.  A member of the 
phosphatidylinositol-3 kinase-related kinase (PIKK) family, ATM is 
activated in response to double-strand break (DSB) damage.  ATM also 
plays a role in non-homologous end joining (NHEJ).4   ATM can be 
specifically activated upon DNA DSB damage due to ionizing radiation, 
replication errors, general toxic drugs, or by-products of metabolism. 
Initially, ATM is activated upon DNA damage, being recruited to the DSB 
site by the MRN complex (Mre11, RAD50, and NBS1).  At the site of DNA 
damage ATM autophosphorylates then proceeds to affect its downstream 
targets, one of which is p53 (Figure 3).  Mutation of ATM leads to the 
autosomal recessive disorder ataxia-telangiectasia (A-T).  This disease is 
characterized by cerebellar ataxia (gross lack of coordination due to 
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cerebellum dysfunction) and oculocutaneous telangiectasia (small dilated 
blood vessels in the eyes).  Individuals with A-T also have symptoms of 
growth retardation, pre-mature aging, hypersensitivity to ionizing radiation, 
and an increase in lymphoma tumorogenesis.24   ATM can function as an 
upstream regulator of a number of proteins and is this involved in several 
cellular processes including cell cycle arrest, DNA repair and apoptosis.   
Because ATM plays such an integral role in DNA damage repair 
and tumorigenesis, some researchers have explored the possible role the 
ATM gene has in CML.  The initial thought was that ATM might have some 
effect in the transformation from the chronic phase of CML to blast crisis, 
due to the association between the complex karyotypes of blast crisis and 
possibly defective DNA double-strand break repair and interaction 
between Abl and ATM.33   
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Figure 2. Imatinib Mechanism of Action 
 
P53 plays a pivotal role in tumor surveillance and tumorogenesis.  
As a master regulator, p53 possesses the ability to signal simple cell cycle 
arrest or push further to apoptosis.  In cell cycle arrest, p53 can signal the 
continued arrest at the G1/S phase through p21, which can act as an 
inhibitor of CDK2/cyclin E.  Prolonged activation of p53 leads to apoptosis 
through a variety of possible proteins, including Bax, NOXA, P53AIP1, and 
PIDD42.  P53 has the ability to activate a diverse variety of genes.  Some 
of these genes modulate DNA repair, cellular senescence, differentiation, 
angiogenesis, longevity, and oxidative stress, just to name a few.8  ATM 
serves as an upstream regulator of p53 through activation of CHK2.  This 
activation (of p53), is one step in the process of cell cycle arrest due to 
DNA DSB damage.  While p53 halts the cell cycle at G1, via p21, it will 
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also up-regulate proteins to address the DNA damage directly through 
repair.  If repair of the DNA damage is unsuccessful then p53 is 
instrumental in initiating apoptosis. 
One downstream target of p53 is mTOR (mammalian target of 
rapamycin resistance).  It is through mTOR that p53 works to control 
cellular senescence and quiescence.  Quiescence is the temporary halting 
of the cell cycle, a period in which division does not take place.  During 
this stage cells can be resting or attempting to repair damaged DNA.  
Quiescence is contrasted to senescence, in which cells have lost the 
ability to divide.  A senescent state may be activated in cells that are 
receiving conflicting growth/death signals, or that have severely shortened 
telomeres.  Depending on further signaling, the cell can revert back to a 
quiescent state, proceed to apoptosis, or even enter into a state known as 
autophagy (self-eating).  It is coming out now in literature that these three 
states are closely inter-related, and p53 sits nearly at the center.  
The serine/threonine protein kinase, mTOR is a member of the 
PIKK family and plays a role in the regulation of autophagy, cell growth, 
cell proliferation, cell survival, and protein synthesis and transcription 
(Hay, Beevers, Bandhakavi).  mTOR has an important role in the induction 
of cellular senescence by p53 and has even been linked to DNA damage 
repair (DDR) through ATM.  It has been suggested that the ability of p53 
to induce senescence or quiescence is linked to inhibition of mTOR.  
Korotchkina, et al., determined that cells normally fated for senescence 
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could be reverted back to quiescence through p53 regulation of mTOR.27  
The group determined that, in quiescent cells, p53 would inhibit mTOR 
ensuring the quiescent state, but if mTOR was activated that quiescence 
would be converted to senescence.  In senescent cells, p53 caused cycle 
arrest without inhibiting mTOR and thus ensured senescence.  If mTOR 
was inhibited in these cells, then quiescence could be restored.  
 
 
Figure 3. Pathway for ATM Regulation of Cell Cycle Arrest, DNA 
Repair, and Apoptosis 
 
P38 and p27 
 Another potential activator of p53 is p38MAPK (mitogen-activated 
protein kinase).  There are four different p38 family members (α, β, γ, and 
δ), the most prevalent and important of which is p38α.  A different gene 
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encodes each member, and expression varies in different tissue types, 
however p38α is ubiquitously expressed in most tissue types at significant 
levels.  Activation of p38 occurs through phosphorylation on both a 
threonine and a tyrosine residue in the activation loop of the protein.  How 
these phosphorylation events occur is dependent upon the activating 
pathway.  In the canonical pathways MAP2Ks will phosphorylate p38 on 
threonine 180 and tyrosine 182.  Alternate paths toward p38 activation 
have also been described.  The cascade leading to p38 activation can 
start with a number of signals including UV irradiation, osmotic shock, 
cytokines, and ROS.  P38 activation by ROS is noted as being through 
canonical activation via MKK3 or MKK6.34   This activation has 
downstream effects on p53, and can lead to premature senescence.  P38 
has also been linked to ATM activation through regulation of oxidative 
stress.20, 28,35   
 Another protein that has been linked to cellular senescence is the 
Cdk inhibitor p27Kip1.  P27Kip1 is a member of the Cip/Kip family of cyclin 
dependent kinase (Cdk) inhibitors along with p57Kip2, and p21Cip1.  P27Kip1 
functions as an upstream regulator of Cdk4 and Cdk2 complexes.  It is 
through the regulation of Cdk4 and Cdk2 complexes that p27Kip1 is able to 
arrest cells at G1.  How P27Kip1 regulates Cdk2 and Cdk4 is still being 
discussed in literature.  Evidence has come out indicating that while 
p27Kip1 can inhibit Cdk2 complexes, regulation of Cdk4 complexes may be 
through activation.6   Members of the Kip/Cip family, in general, are 
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portrayed as being potent inhibitors of cyclin-Cdk complexes and p27Kip1 is 
reported to be active in quiescent cells but not in cycling cells.  The 
inhibitory potential of p27Kip1 is dependent on the cellular context.5, 6   For 
example, Cip/Kip proteins adopt specific tertiary structure upon binding to 
other proteins.  This conformational flexibility may modify the folding of the 
Cip/Kip proteins and modulate their ability to inhibit cyclin-CDK 
complexes.5  This is likely why members of Cip/Kip are able to interact 
with so many different partners.  Regulation of p27Kip1 is through 
phosphorylation and protein-protein interactions.  The phosphorylation of 
p27Kip1 can alter its affinity for different Cdk complexes, other proteins and 
their subcellular localization.5 Research has indicated that treatment with 
Imatinib will cause an increase in p27Kip1 expression and that the nuclear 
accumulation of p27Kip1 is in part responsible for the anti-proliferative 
activity of Imatinib.7  
 
S9 – Senescent Pre-B Cell, Cell Line 
 Our lab is currently exploring the use of a cell line of Pre-B cells 
harvested from severe combined immunodeficient (SCID) mice.  This cell 
line also has a defect in the catalytic subunit of DNA-dependent protein 
kinase (DNA-PKcs), a DNA damage repair protein.  After harvesting these 
cells were transformed by infection with a temperature sensitive Abelson 
murine leukemia virus (ts-Ab-MuLV).  This temperature sensitivity 
conferred a constitutively active v-Abl in the S9 cell line that could be 
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inactivated by shifting the cells from the permissive temperature (33°C) to 
the non-permissive temperature (39°).  Initially created to monitor V(D)J 
recombination, these cells were found to arrest at G1 phase when v-Abl 
was inactivated (shifted to 39°C) as expected.  However, when v-Abl is 
reactivated the cells do not return to their normal cell cycle.  Instead they 
enter a state of prolonged G1 arrest.  Some cells were able to escape the 
G1 arrest, returning to the cell cycle.  When grown in culture, these cells 
have been found to be resistant to cell cycle arrest and to arrest induced 
by Imatinib.  This goes along with their transformation to a malignant cell 
line.  The purpose of this study was to determine what the cause of the 
temperature-induced prolonged G1 arrest of these S9 cells in an effort to 
see if the S9 cell line could serve as a model for Ph+ ALL. 
 
Materials and Methods 
 
Cell Culture 
S9, A70, and SB 1.1 cells were cultured in RPMI 1640 media with 
10% fetal bovine serum, 1mM L-glutamine, 100 U/ml streptomycin, 
100ug/ml penicillin, and 50uM β-mercaptoethanol.  S9 cells were 
maintained at 33°C (v-Abl permissive temperature) in 5% CO2.  V-Abl 
inactivation was accolplished by incubating S9 cells at 39°C in 5% CO2 for 
two days.  Re-activation of v-Abl was through shifting S9 cells back to the 
permissive temperature (33°C).  A70 and SB 1.1 cells were maintained at 
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37°C in 5% CO2.  A70 is a pre-B cell line that has been transformed with 
Ab-MuLV.  SB 1.1 is also a Ab-MuLV transformed pre-B cell line, however 
this line was derived from a DNA-PK knockout mouse and has a defective 
DNA-PK. Because A70, and SB 1.1 cells did not have a temperature-
sensitive v-Abl, inhibition of v-Abl was accomplished through chemical 
inhibition with STI571 (Imatinib).  
 
Drug Treatments 
To determine what effect different inhibitors had on senescence in 
S9 cells we treated them with either pan-PI3K-inhibitor, LY294002, or 
ATM inhibitor KU55933 (both from CalBiochem/EMD).  LY294002 was 
applied to cells at a concentration of 10µM, and KU55933 at a 
concentration of 8µM for 48hrs at 39°C then cells were washed in PBS 
and re-incubated in either fresh control media or fresh media containing 
LY294002 or KU55933 for another 48hrs.  Alternate S9 v-Abl inactivation 
and v-Abl inactivation in A70, and SB 1.1 was accomplished through 
treatment with 1µM STI571 (LC Laboratories) for 48hrs.  As with the other 
inhibitors, after 48hrs the STI571 was washed off and the cells re-
incubated in control media.  All drugs were prepared in DMSO with a final 
DMSO concentration of 0.1%.  Control media was prepared with 0.1% 
DMSO to mirror drug treatment DMSO concentrations. 
 
Cell Cycle Analysis 
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Flow cytometry was run on a FACSCaliber, (BD Biosciences) 
according to the following: 250µl of cell suspension was centrifuged at 
1500rpm for 5 minutes at 4°C.  Supernatant was removed and cells were 
re-suspended with equal amounts of RNAse A (2mg/ml in 1.12% sodium 
citrate) and Propidium Iodide (100ug/ml in 0.2% triton-x 100/0.1% sodium 
citrate). The FACSCaliber recorded a total of 10,000 events.  
Fluorescence intensity was analyzed with a FL2-A histogram using Cell 
Quest Pro software (BD Biosciences). 
 
Western Blot Protein Detection 
Cells were counted, washed in cold PBS, then lysed in lysis buffer 
and incubated on ice for 30 minutes.  Equal amounts of protein lysate from 
each sample (~ 2million cells or 65ng total protein as determined by 
Bradford assay) were separated via SDS-PAGE then transferred to PVDF 
membrane while on ice.  Membrane were blocked in 5% BSA in tris-
buffered saline with 5% Tween 20 (TBST) then incubated with primary 
antibody overnight at 4°C.Phospho-p53, p53, phospho-p38, p38, and p27 
antibodies were purchased from Cell Signaling. GAPDH was purchased 
from Sigma –Aldrich, and Actin from Santa Cruz Biotechnology.  After 
primary antibodies, membranes were incubated at room temperature with 
an appropriate peroxidase-conjugated secondary antibody (anti-rabbit, 
anti-mouse or anti-goat) for one hour.  Primary antibodies were used at 
1:1000 dilutions, while secondary antibodies were at 1:5000 dilutions.  
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Detection of specific bands was by using enhanced chemiluminescent 
reagents from Pierce (Thermo Scientific).  Luminescent signal was 
transferred to blue autoradiography film (Santa Cruz Biotechnology) and 
developed.
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Results 
 
ATM Inhibition Allows S9 cells to Re-enter cell cycle After v-Abl 
Reactivation 
 The first experiment performed was to see if inhibition of certain 
pathways could break the senescence phenotype in S9 cells and get them 
to re-enter the cell cycle.  We used two different PI3K kinase inhibitors to 
determine if their disruption could release S9 cells from G1 arrest. We 
treated S9 cells with two different PI3K inhibitors while shifting the cells up 
to the non-permissive temperature.  The cell cycle was analyzed via flow 
cytometry after two days of v-Abl inactivation (at 39°), and every day 
following re-activation.  
 
 
Figure 4. Flow cytometry of S9 cells with v-Abl active (top) or inactive 
(bottom).  
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 Cell Cycle.  Cell cycle profiles for each drug were determined by 
permeabilization and propidium iodide (PI) staining.  Because PI stains the 
DNA directly, DNA content can be measured at different wavelengths.  
This information can then be extrapolated to the accumulation of DNA in 
different phases of the cell cycle. The inhibitors used were LY294002, and 
KU55933.  The first, LY294002 is a PI3K inhibitor that acts reversibly and 
has been shown to block PI3 kinase-dependent Akt phosphorylation and 
kinase activity.  The second is a small molecule inhibitor specific for ATM 
and is called KU55933.  Figures 4 & 5 represents an example of the 
output from our flow cytometric analysis of the PI staining of S9 cells 
under treatment with LY294002 and KU55933.  The M1 region represents 
cells undergoing apoptosis.  M2 is cells in G0/G1, M3 is cells in S phase, 
and M4 represents cells in G2.  Aneuploid cells are seen in M5.  While 
treatment with LY294002 offered no real change in G1 arrest after v-Abl 
reactivation, treatment with KU55933 displays a robust re-entry into the 
cell cycle within 2 days after v-Abl re-activation (Figure 6).  From this we 
determined that specific inhibition of ATM was able to release the G1 cycle 
arrest and allow S9 cells to re-enter the cell cycle.  
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Figure 5. Flow cytometry of S9 cells after v-Abl re-activation.  
Inhibition of PI3K (top), or inhibition of ATM (bottom).  S9 cells were 
treated with either LY294002 (PI3K inhibitor) or KU55933 (ATM inhibitor) 
and shifted to 39°C for 48hrs, washed in PBS, and re-incubated with 
treated media at 33°C to re-activate v-Abl. Results shown are 48 hours 
after v-Abl re-activation. 
 
 
Prolonged G1 Arrest of S9 Not Dependent upon mTOR 
 Studies have indicated that there is a relationship between 
the PI3K kinase mTOR and cellular senescence.17  Korotchkina, et al. 
have recently shown that mTOR can have an effect in the decision 
between senescence and quiescence in p53-arrested cells.  The group 
used nutlin-3a to transiently induce p53 in normally quiescent or in 
senescent-prone cells.  They found that the quiescent cells could be 
forced into senescence, while the senescent cells were pushed toward 
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reversible quiescence and the state of mTOR (active or inactive) seemed 
to be at the center of this.  
 
 
Figure 6. ATM inhibition allows S9 cells to re-enter the cell cycle.  S9 
cells were shifted up to 39°C to in-activate v-Abl for 48hrs.  One set was 
PI3K inhibited, another was ATM inhibited.  After 48hrs of v-Abl 
inactivation, cells were washed with PBS, then incubated in either 
treatment media (PI3K Inhibited, ATM Inhibited) or in control media (PI3K 
Inhibited WO [washed off], ATM inhibited WO [washed off]).  As controls, 
untreated S9 cells were shifted to 39°C for 48hrs, washed, and shifted 
back to 33°C or kept at 33°C. 
 
Our S9 cells enter into a senescent state when v-Abl is reactivated 
and do not return to their normal growth cycle.  The reason for this 
senescence is currently unknown.  We tried inhibiting mTOR via treatment 
with rapamycin to see if this senescent phenotype was the result of mTOR 
induction.  Rapamycin is an immunosuppressant drug used to prevent 
rejection in organ transplants.  Rapamycin works by binding to cytosolic 
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FK-binding protein 12 (FKBP12), then the rapamycin-FKBP12 complex 
binds to mTOR complex 1 (mTORC1) inhibiting the cell’s response to 
interlukin-2 (IL-2), thereby blocking the activation of both T and B cells.  In 
our experiments we tested to see if by shutting down mTOR with 
rapamycin we could force our normally senescent S9 into quiescence.  
We treated S9 cells with 1µM rapamycin and shifted up to the non-
permissive temperature for 2 days then washed in PBS and shifted back 
to the permissive temperature for 2 days.  Upon shift back the cells were 
either re-incubated in media with 1µM rapamycin or untreated media.  Cell 
cycle was analyzed via flow cytometry after 2 days at the non-permissive 
temperature and 2 days after v-Abl reactivation.  After 2 days of v-Abl 
inactivation all cells were arrested at G1 regardless of the treatment.  Two 
days after v-Abl reactivation S9 cells were still arrested at the G1 phase 
(Figure 7).  Unlike ATM inhibition, inhibition of mTOR did not release the 
cellular senescence.  
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Figure 7. Prolonged G1 arrest in S9 cells is not mTOR dependent. S9 
cells were either treated with rapamycin or left untreated and shifted up to 
39°.  Cells were treated with rapamycin for 48hrs then washed in PBS, re-
incubated in control media (RM Rinsed), or rapamycin treated media (RM 
Continuous) at 33 degrees. 
 
Prolonged G1 arrest phenotype unique to our S9 cell line 
We also attempted to see if this condition was unique to our S9 
cells or if it could be seen in similar B cell lines.  We used the scid cell line 
SB 1.1 with the v-Abl transformed pre-B cell line A70 as a control.  While 
both of these cell lines are immortalized, the v-Abl that they are 
transformed with is not temperature sensitive.  Therefore we had to 
inactivate v-Abl using the BCR-Abl inhibitor STI571 (commercially known 
as imatinib, marketed as Gleevec).  First we treated the cells with 1µM STI 
for 2 days to inactivate v-Abl.  We also treated some cells with 8µM 
KU55933.  After two days the cells were washed in PBS and re-incubated 
in either fresh media or media containing KU55933 for another two days.  
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Cell cycle analysis was performed after two days of v-Abl inactivation and 
two days after v-Abl reactivation.  As seen in Figure 8, both A70 and SB 
1.1 arrest with STI treatment and return to their cycle after STI is removed.  
ATM inhibition does not seem to have much if any significant effect on 
cycle arrest or return.   
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Figure 8. Prolonged G1 Arrest Unique to S9 Cells.  A70 (WT) and SB 
1.1 (SCID) cells had their v-Abl inactivated by treatment with STI571 
(Imatinib) for 48hrs then re-activated by washing the imatinib off and re-
incubating the cells in control media.  One set of cells had ATM inhibited 
through treatment with KU55933.  ATM inhibition was continued 
throughout the experiment.  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Prolonged G1 Arrest of S9 is Temperature Dependent 
 Our S9 cell line mimics Imatinib treatment through shifting the cells 
to the non-permissive temperature, thus inactivating v-Abl.  In order to 
determine if the senescence seen was unique to the temperature-sensitive 
mutant we inhibited v-Abl using imatinib at the permissive temperature for 
48hrs, then washing the drug off and examining the cells’ cycle recovery 
48hrs after drug removal.  Imatinib inactivated S9 cells arrested at the G1 
phase after two days treatment with 1µM Imatinib.  Once the drug was 
washed off S9 cells quickly returned to their cell cycle (Figure 9). 
 
 
 Figure 9. Senescence in S9 Cells is Temperature Dependent.  
Comparison of Imatinib inactivated v-Abl to v-Abl inactivation through 
temperature shift in S9 cells with or without ATM inhibition. 
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Senescence in S9 is dependent on p27 activation 
 Through analysis of the cell cycle we have seen that senescence in 
S9 cells is dependent on how v-Abl is inactivated.  When v-Abl is 
inactivated through temperature shifting the cells fail to re-enter the cell 
cycle upon v-Abl re-activation, unless ATM is inhibited.  If v-Abl 
inactivation is from treatment with Imatinib, then S9 cells can re-enter the 
cell cycle regardless of ATM inhibition. (Figure 9)  ATM is a 
serine/threonine kinase that functions predominately as a DNA damage 
sensor with many downstream targets including p53.  To determine how 
ATM was able to render temperature shifted S9 cells in senescent state 
but not cells whose v-Abl was chemically inhibited, we looked at the 
protein profiles of S9 cells under both treatment conditions.  Protein 
lysates were collected and prepared according to the method previously 
mentioned.  Samples were collected two days after v-Abl inactivation and 
two days after v-Abl re-activation.    
The first protein examined was p53.  P53 is a major downstream 
target for ATM, and plays a leading role in G1 checkpoint arrest.  
Phosphorylation of p53 by ATM has been shown to contribute to cell cycle 
arrest at G1 through p21 (Reinhardt).  Phosphorylation of p53 is the critical 
step in cell cycle arrest and in apoptosis.  It has been known for years that 
p53 serves as a ‘Master regulator’, being a deciding factor between cell 
cycle arrest and apoptosis.  Mutation or inactivation of p53 is found in over 
50% of cancers.  Additionally, p53 works with mTOR to induce cell 
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senescence or quiescence, thus its potential involvement with our S9 cells 
was of particular interest.  
Figure 10. Western blots: A: A70 and SB 1.1 with v-Abl inactive (top) 
and re-activated (bottom); B: S9 cells with ATM inhibited (KU), v-Abl 
inactive (39), re-active for 1 day (SB 1), 2 days (SB2); C: S9 treated with 
Imatinib alone, or Imatinib+ KU55933.  
 Cells shifted from the non-permissive temperature and back again 
have a similar level of p53 phosphorylation regardless of ATM inhibition 
(Figure 10 - B).  This characteristic is seen after 1, and 2 days of v-Abl re-
activation. This general pattern (similar levels of p53 phosphorylation) is 
also seen in S9 cells treated with imatinib or imatinib and KU55933, both 
at two days of v-Abl inactivation and two days after re-activation.  From 
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this we can gather that regardless of the method of v-Abl inactivation, p53 
will be phosphorylated, though not necessarily by ATM (when ATM is 
inhibited). 
 Researchers have found evidence-linking ATM to p38MAPK and 
ROS signaling23.   As a response to stress stimuli, p38 will be 
phosphorylated to help activate downstream targets effecting cell 
differentiation and apoptosis.  Since our S9 cells, when shifted to their 
non-permissive temperature will arrest at G1 but do not necessarily 
undergo apoptosis we wanted to see if p38 signaling was intact in this cell 
line.  S9 cells maintain some level of p38 phosphorylation at all times.  
When v-Abl is inactivated through a temperature shift, inhibition of ATM 
increases phosphorylation over controls (Figure 11).  This holds true even 
when v-Abl is reactivated (cells shifted back to 33°C).  When S9 cells are 
treated with imatinib, p38 phosphorylation increases in treated cells 
(Imatinib+KU and imatinib alone) when v-Abl is inactivated.  This increase 
does not seem to continue once v-Abl is re-activated. 
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Figure 11. Western blots of A70, SB 1.1 and S9. A: v-Abl inactive (top), 
v-Abl re-activated (bottom); B: ATM inhibited (KU), cell shifted (v-Abl 
inactive), or shifted back (SB, v-Abl Re-active); C: Cell treated with 
Imatinib, or Imatinib+KU 55933 (ATM inhibited). 
  
P27Kip1 is tied to G1 cycle arrest and is similar in DNA sequence and 
function to p21Cip1.  This cell cycle progression inhibitor works by binding 
to targets such as Cyclin D or Cdk2 and inhibiting their activity thus 
holding the cell in the G1 phase5.  Treatment of CML cells with imatinib 
has been shown to increase levels of p27Kip1 7.  We thought it would be 
interesting to see if the increase in p27Kip1 could be seen in our S9 cells 
with imatinib treatment or with temperature shift.  When S9 cells are 
treated with imatinib, as is expected p27Kip1 is expressed after two days of 
imatinib treatment.  We examined this in the A70 and SB 1.1 cells for 
consistency.  When v-Abl is inactivated via temperature shift p27Kip1 is not 
activated (Figure 12).  It seems that the prolonged G1 arrest displayed by 
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S9 cells upon temperature dependent inactivation of v-Abl is dependent 
on or related to p27Kip1 activation. 
 
Figure 12. Western blots of A70, SB 1.1 and S9. A: v-Abl inactive (top), 
v-Abl re-activated (bottom); B: ATM inhibited (KU), cell shifted (v-Abl 
inactive), or shifted back (SB, v-Abl Re-active); C: Cell treated with 
Imatinib, or Imatinib+KU 55933 (ATM inhibited). 
 
Discussion 
 
 The S9 cell line was initially created in order to study the dynamics 
of V(D)J recombination.  Derived from pre-B cells harvested from SCID 
mice, then transduced with ts-Ab-MuLV, S9 cells will arrest at G1 when v-
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Abl is turned off.  Once v-Abl is turned back on, by shifting the cells from 
the non-permissive to the permissive temperature, the G1 arrest continues. 
The molecular biology behind this continued arrest is a matter we are still 
working out.  Looking at it from a cancer research perspective, S9 cells 
seem to mimic Imatinib treatment by exiting the cell cycle when shifted, 
but they do not apoptosis.  Treatment of Ph+ leukemia with Imatinib does 
not actually drive the cancer into apoptosis, rather it forces them into a 
cellular senescence that with treatment continues, until some cancer cells 
develop a resistance.  The difference in this scenario is that the leukemia 
is stuck at G1 only until treatment is halted or resistance is developed.  S9 
cells will continue their arrest even after Abl has been turned back on.  S9 
cells that break the prolonged G1 arrest phenotype on their own will 
progress into a malignancy that is resistant to Imatinib treatment and v-Abl 
inactivation.  Given these observations, we think that S9 cells can offer a 
possible glimpse into the events surrounding the development of Imatinib 
resistance in CML and Ph+ ALL. First, we needed to determine the 
molecular mechanisms behind the observed senescence in the 
temperature sensitive S9 cells. 
 We first sought to determine, what, if anything could break S9 cells 
free from their senescence.  We treated S9 cells with a pan-PI3K inhibitor 
and an inhibitor of ATM and found that ATM inhibition of S9 cells at the 
time of v-Abl inactivation would permit re-entry into the cell cycle after v-
Abl re-activation.  So far this re-entry seems to be dependent on ATM 
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inhibition only at the time of v-Abl inactivation, with little to no effect seen if 
ATM is inhibited only at re-activation or inhibition is discontinued at v-Abl 
re-activation (data not shown).  Inhibition of PI3K kinases in general does 
not have the same effect. 
 ATM is heavily involved in the DDR pathway and plays a role in 
V(D)J recombination.  Research has shown that ATM can function directly 
in the repair of chromosomal DNA double-strand breaks.  During 
lymphocyte antigen receptor generation, ATM maintains the DNA ends in 
repair complexes.8   ATM has been linked to regulation of c-Abl and 
retinoblastoma (Rb) protein.28, 35 Activation of ATM was thought to only be 
through DNA damage, however, recently it has been noted that oxidative 
stress can also activate ATM even in the absence of DNA damage.20, 37,47   
With all that it has been linked to in previous research it is conceivable that 
ATM could be activating a downstream target that is able to hold the cells 
in an arrested state even after v-Abl reactivation.  Because ATM sits 
upstream of proteins Chk2 and p53, and their downstream targets have a 
direct affect on senescence, it is not completely unexpected that ATM 
inhibition might be able to break the senescence phenotype in S9 cells.  
It has been long known that ATM is an upstream activator of p53.  
Activation of p53 has been linked to quiescence (temporary cycle arrest), 
senescence (permanent cycle arrest), apoptosis, and DNA repair.  When 
v-Abl is inactive it is likely that stress levels in the cells can increase and 
thus p53 would be activated to help initiate DNA repair and cycle arrest. 
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However the phosphorylation of p53 in S9 cells does not seem to be 
entirely dependent on ATM. Phosphorylation levels of p53 in S9 cells are 
not significantly higher or lower than the controls regardless of how v-Abl 
is inactivated.  This may differ from the A70 and SB 1.1 cell lines used for 
comparison.  Both of these lines have slightly lower p53 phosphorylation, 
though ATM inhibition does not seem to make a significant difference in 
phosphorylation.  This could indicate that a change in p53 in S9 or in a 
p53 related pathway.  According to our protein analysis, p53 is still 
phosphorylated in S9 cells, even when ATM has been inhibited.  This 
points toward p53 being activated through something other than ATM.   
One thing that can activate p53 is oxidative stress.  The start of this 
stress can be signaled through one of the MAPKs.  One of the more active 
signal transducers is p38.  This protein is ubiquitously expressed at 
significant levels in most cell types.13   In our experiments the 
phosphorylation of p38 was high in A70, SB 1.1, and S9 cells when v-Abl 
was inactivated with Imatinib treatment, though ATM inhibition did not 
have any significant effect on p38 phosphorylation under this treatment.  
This is in contrast to p38 phosphorylation in S9 cells when v-Abl is 
inactivated through a temperature shift.  In the temperature shift 
experiment, ATM inhibition effectively increases p38 phosphorylation.  It is 
noted that p38 phosphorylation is high in the S9 cell line normally, so it 
may be more correct to say that phosphorylation of p38 is low in 
temperature inactivated S9 cells.  Once v-Abl is reactivated in S9 cells, 
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p38 phosphorylation levels do go down regardless of how v-Abl was 
inactivated.  Since it is known that oxidative stress can activate p53, it is 
possible that p38 could be activating p53 in these cells and not ATM.  This 
would indicate that v-Abl inactivation is somehow increasing the levels of 
p38 phosphorylation. 
 Korotchkina, et al., found evidence intricately linking p53 and the 
PIKK mTOR to cellular the decision over quiescence or senescence.  
Through their studies they found that p53 pushed cells toward senescence 
by failing to inhibit mTOR, and mTOR causing the senescence seen.  To 
determine if mTOR might be somehow causing the senescence in S9 cells 
we tried inhibiting mTOR by treating the cells with rapamycin in an 
experiment mirroring the one used for ATM inhibition.  Inhibition of mTOR 
did not release cellular senescence in S9 cells upon v-Abl re-activation.  
So activation of mTOR was not causing the senescence seen. 
 One major difference between our S9 cells and leukemia cells 
bearing the Ph chromosome is that inactivation of v-Abl in S9 cells can be 
accomplished through shifting to a non-permissive temperature.  We 
wanted to see if v-Abl inactivation would cause senescence in non-
temperature sensitive cell lines, so we repeated the experiment with v-Abl 
transformed cells A70, and SB 1.1, using SB 1.1 as a DNA-PK knockout 
line and A70 as a wild type.  While treatment with the Abl inhibitor Imatinib 
did induce cycle arrest, this arrest was not permanent and the cells quickly 
re-entered the cycle upon Imatinib removal.  ATM inhibition had only a 
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minor effect in the cells, allowing slightly less cycle arrest 48 hours after v-
Abl inactivation and slight slowing of the return to the cell cycle.    
 Next we tried inhibiting v-Abl in S9 cells using Imatinib instead of 
via temperature shift.  Imatinib did arrest the cells as expected.  What was 
not expected was the re-entry into the cell cycle after Imatinib removal.  
Inhibition of v-Abl through Imatinib would not cause senescence in S9 
cells.  ATM inhibition had little significant effect on the re-entry.  Inhibition 
of v-Abl with Imatinib did not produce as complete an arrest as 
temperature shifting usually does.  All of these factors would indicate that 
there is a difference between inhibiting v-Abl and simply turning it off as is 
done in S9 cells that are shifted.  
 Armed with the knowledge that temperature dependent v-Abl 
inactivation was intrinsically different than chemical dependent v-Abl 
inactivation we sought to find what proteins are different between the two 
types of inactivation.  It has been noted by some researchers that p27Kip1 
is activated in Imatinib treated cells derived from CML patients.  P27 Kip1 is 
a cyclin dependent kinase (Cdk) inhibitor that can bind and prevent the 
activation of cyclin E-CDK2 or cyclin D-CDK4 complexes.  This inhibitory 
effect allows p27 some control over cell cycle progression at G1.  P27Kip1 is 
a member of the Cip/Kip family that includes p57Kip2 and p21Cip1/Waf1.  In 
addition to DNA sequence and structural similarity, all members of this 
family are able to bind to different classes of cyclin and Cdk molecules.5   
Borriello, et al., investigated the relationship between p57Kip2 and the 
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BCR-Abl kinase inhibitor Imatinib and found that p57Kip2 would accumulate 
in Ph+ cells prior to p27Kip1 accumulation and thus may be a downstream 
effector of Imatinib.7  
Since p27 Kip1 was involved in G1 arrest we looked at the levels of 
p27 Kip1 in S9 cells treated with Imatinib vs. cells shifted to the non-
permissive temperature.  The p27 Kip1 levels in cells treated with Imatinib 
are higher than those of cells not treated.  Also, inhibition of ATM in shifted 
cells is generally higher than in non-ATM inhibited cells. The only 
exception to this in the S9 cells shifted back to 33°C for two days.  In 
these cells, p27 Kip1 is slightly higher in the controls than in the ATM 
inhibited cells.  Analysis of the p27 Kip1 levels in the A70 and SB 1.1 cells 
indicated that Imatinib treatment could raise p27 Kip1 levels in cells.  
Interestingly, the p27 Kip1 levels decrease only a little when v-Abl is re-
activated in Imatinib treated cells. 
From this information we can conclude that Imatinib inactivation of 
v-Abl will cause G1 arrest in cells possibly through the activation of p27 Kip1 
and independent of ATM inhibition.  Also, temperature induced inactivation 
of v-Abl in our S9 cells causes a permanent G1 arrest that is not through 
p27 Kip1 but can be abrogated by inhibition of ATM.  Inhibition of ATM at 
the time of temperature induced v-Abl inactivation starts a cascade that 
allows p27 Kip1 to be activated in these cells to levels that will allow them to 
re-enter the cell cycle after v-Abl re-activation.  This seems counter-
intuitive in that p27 Kip1 is normally described as an inhibitor of cell cycle 
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progression.  The activation of p27 Kip1 with ATM inhibition is only seen 
during v-Abl inactivation and concludes within 48 hours of v-Abl 
reactivation.  This is different than cells treated with Imatinib.  Imatinib 
treated S9 cells have higher p27 Kip1 levels throughout treatment with ATM 
inhibitor KU55933 and do not depend on v-Abl inactivation, or this is not 
abated with v-Abl reactivation. 
In S9 cells a temperature shift from permissive to non-permissive 
temperature will inactivate v-Abl causing a permanent cell cycle arrest.  
This cell cycle arrest can be overcome through inhibition of ATM during v-
Abl inactivation and has downstream repercussions on p27 Kip1 activation.  
In the treatment of CML and ALL Ph+, what this means is that ATM may 
be allowing the malignant cells to re-enter the cell cycle.  This is important 
because while Imatinib can be used to treat CML and ALL Ph+, resistance 
to Imatinib can develop.  Additionally, if treatment is halted, then the 
condition returns.  ATM may be how these malignant cells are able to 
return.  Further examination of the senescent phenotype in S9 cells may 
allow us to determine more key players in the senescence seen.  If this 
senescence can be recapitulated in Ph+ leukemia, then there is hope that 
the disease may finally be eradicated. 
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